Sign In
Buy VKTX
$32.37
+1.99 (+6.55%)
At Close: Jun 22, 2026
Better Weight Loss Stock: Amgen or Viking Therapeutics?
11:05am, Thursday, 22'nd May 2025
Investors looking to cash in on the fast-growing market for weight management medicines will naturally turn to the two leaders in this area, Eli Lilly and Novo Nordisk. However, several other companie
Viking Therapeutics: Weight-Loss Story Remains Intact
07:24am, Thursday, 22'nd May 2025
Viking Therapeutics remains a promising weight-loss drug biotech due to the enrollment of new promising trials. The weight-loss sector's momentum has faded some, but Eli Lilly and Novo Nordisk have st
Viking Therapeutics: A High Potential Biotech Play With Manageable Risks
11:30am, Tuesday, 20'th May 2025
Viking targets massive, validated markets with GLP-1/GIP and THR-β agonists, offering injectable and oral alternatives with promising Phase 2/3 results. Positioned as a second-line, tolerable, patien
Viking Therapeutics: Near-Term Catalysts And Competitor Readouts
06:49am, Tuesday, 20'th May 2025
VKTX's VENTURE-Oral study of VK2735 has completed enrollment, with a readout set for H2'25. The company's phase 3 program on subcutaneous VK2735 is getting underway, although given it will contain tho
Why Viking Therapeutics Stock Bumped 3% Higher Today
05:20pm, Friday, 16'th May 2025
A major C-suite change at a potential competitor was a key factor behind the rise of Viking Therapeutics (VKTX 3.61%) stock on Friday, which closed the trading session 3% higher. That figure was well
3 Monster Stocks in the Making
11:15am, Sunday, 11'th May 2025
Think of some of the biggest and most successful stocks on the market. Now, go back 20 or 30 years.
Why Viking Therapeutics Stock Surged Nearly 20% Higher in April
04:33am, Tuesday, 06'th May 2025
One of the best catalysts for a stock's rise is the withdrawal of a rival. That was an important dynamic behind the double-digit-percentage rise of biotech Viking Therapeutics' (VKTX 0.32%) stock in A
Why Viking Therapeutics Stock Was Victorious This Week
05:48pm, Friday, 02'nd May 2025
Viking Therapeutics (VKTX 2.85%), a biotech that has shot to prominence thanks to a weight-loss drug it is developing, was a winning stock this week. Over the course of the past five trading days, its
Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday
11:55am, Friday, 02'nd May 2025
Positive jobs news and positive rumors out of China are lifting stock markets today, as the U.S. Labor Department reports adjusted nonfarm payrolls grew by 177,000 jobs in April, and CNBC reports that
Where Will Viking Therapeutics Be in 3 Years?
04:20am, Friday, 02'nd May 2025
The pharmaceutical and biotechnology business tends to be about hitting home runs more than just getting on base. A highly successful drug, sometimes referred to as a blockbuster, can build up a small
1 Beaten-Down Stock to Buy and Hold for 10 Years
05:47am, Thursday, 01'st May 2025
Viking Therapeutics (VKTX 3.44%) was one of the hottest biotech stocks of 2024; its shares soared last year following excellent clinical progress. However, things have been very different in 2025, at
Prediction: Pfizer's Loss May Be Viking Therapeutics' Gain
03:15am, Wednesday, 30'th Apr 2025
Big pharmaceutical companies as well as smaller biotechs have been hoping to score a win in one of today's highest-growth treatment areas: and that's weight loss. Analysts forecast a compound annual g
Why Viking Therapeutics Stock Popped Again Today
12:24pm, Tuesday, 29'th Apr 2025
Shares of Viking Therapeutics (VKTX 11.41%) jumped 12.5% through 11:40 a.m. ET on Tuesday on further support from Wall Street analysts.
Why Viking Therapeutics Stock Popped Today
11:06am, Monday, 28'th Apr 2025
Viking Therapeutics (VKTX 0.40%) stock inched 2.3% higher through 10:20 a.m. ET Monday, and for a most curious reason.
Viking Therapeutics Stock May Struggle After As-Expected Report
08:02am, Friday, 25'th Apr 2025
Viking Therapeutics Inc. NASDAQ: VKTX reported earnings after the market closed on Apr. 23. The stock is pushing higher as investors attempt to sort out a report that delivered no real news that inves
